Document Detail


Indobufen in secondary prevention of transient ischaemic attack. Multicentre Ischaemic Attack Study Group.
MedLine Citation:
PMID:  2193837     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The secondary prevention of transient ischaemic attacks was assessed in 270 patients treated orally with 100 mg indobufen given twice daily for 12 months. After 1 month's treatment, the average number and average incidence of transient ischaemic attacks were reduced significantly (P less than 0.001) and remained suppressed throughout the treatment period. Treatment was interrupted in 17 patients: in two because of side-effects (gastric disturbances); in 10 because of fatal events (six completed strokes, two myocardial infarcts and two unrelated deaths); and in five due to poor protocol compliance. Progression to reversible ischaemic neurological deficit occurred in five patients. Most side-effects were mild and transient, mainly occurring in the first month of treatment. Overall, indobufen was judged to have good efficacy and safety by both patients and physicians.
Authors:
J Rogan
Related Documents :
16224097 - In-hospital medical complications and long-term mortality after ischemic stroke.
18438127 - Resection of carotid body tumors: results of an evolving surgical technique.
24516987 - The impact of obesity on early mortality after coronary artery bypass grafting.
17272777 - Prior statin use may be associated with improved stroke outcome after tissue plasminoge...
24922897 - 13 the ablation effectiveness quotient: a novel marker to predict the success of atrial...
9705097 - Aortic reconstructive surgery for limb ischaemia: immediate and long-term follow-up to ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  The Journal of international medical research     Volume:  18     ISSN:  0300-0605     ISO Abbreviation:  J. Int. Med. Res.     Publication Date:    1990 May-Jun
Date Detail:
Created Date:  1990-08-08     Completed Date:  1990-08-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0346411     Medline TA:  J Int Med Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  240-4     Citation Subset:  IM    
Affiliation:
Medical Department, Farmitalia Carlo Erba ROSCA, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cerebrovascular Disorders / mortality
Female
Humans
Ischemic Attack, Transient / mortality,  prevention & control*
Isoindoles
Male
Middle Aged
Multicenter Studies as Topic
Myocardial Infarction / mortality
Phenylbutyrates / adverse effects,  therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use*
Chemical
Reg. No./Substance:
0/Isoindoles; 0/Phenylbutyrates; 0/Platelet Aggregation Inhibitors; 36690-96-7/indobufen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cefetamet in the treatment of acute sinusitis in adult patients.
Next Document:  A review of long-term safety data with buflomedil.